Denosumab versus zoledronic acid in metastatic breast cancer: A retrospective observational analysis of 24-dose regimens on analgesia and skeletal-related event prevention

Background: Based on available data in the literature, current evidence supporting the analgesic role of antiresorptive drugs is weak. This study compared the efficacy of zoledronic acid (ZA) and denosumab (Dmab) in reducing bone pain and first Skeletal Related Events (SREs) in real world setting. M...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Giacomo Massa, Noemi Simeone, Gabriele Tinè, Paola Bracchi, Rosalba Miceli, Alessandra Pigni, Silvia Lo Dico, Luca Zambelli, Francesca Ricchini, Giulia Valeria Bianchi, Augusto Caraceni, Ernesto Zecca
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	Elsevier 2025-10-01
Cyfres:	Breast
Pynciau:	Bone metastases Bone pain Denosumab Zoledronic acid Skeletal-related events Breast cancer
Mynediad Ar-lein:	http://www.sciencedirect.com/science/article/pii/S096097762500582X
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!